Report Library
All Reports
2015 BioMedTracker AACR Highlights
April 13, 2015
The American Association for Cancer Research (AACR) annual meeting will be held in Philadelphia, PA from April 18–22, 2015. We
highlight presentations related to several hot areas of drug development in this piece:
For our disclosures, please read the BioMedTracker Research Standards.
- Hot on the heels of the launch of Imbruvica (ibrutinib, PCYC/JNJ) and the announcement of ABBV’s acquisition of PCYC, preclinical data suggest that Imbruvica has activity in solid tumors in combination with checkpoint inhibitor immunotherapies. Other Btk inhibitors are in earlier-stage development in various cancer and inflammation-related indications.
- Although Opdivo (nivolumab, BMY) and Keytruda (pembrolizumab, MRK) are leading the pack in PD-1/PD-L1 development, Roche and REGN also have candidates in clinical trials for major solid tumor indications. We expect to see clinical and pre-clinical results from those candidates at AACR. Furthermore, new clinical trial data for pembrolizumab will be presented at an immuno-oncology plenary session; these results portend label expansions for this agent.
- We do not expect major clinical results for chimeric antigen receptor T cell (CAR-T) therapies or other engineered cellular therapies at this meeting, but preclinical presentations may provide insight into future targets (with respect to molecular target and to disease indication) for existing programs.
- Big pharma companies are working on next-generation EGFR inhibitors to tackle resistance mutations to currently available inhibitors. This next wave is led by product candidates originated by AZN and CLVS and may also spare wild-type EGFR, reducing the incidence and severity of side effects.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: | Oncology |
| Indications Covered: | Castleman's Disease |
Additional Resources: